Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 261 participants.
Also called NCT03068130
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 261 participants
- Sponsor
- Registry
-
NCT03068130
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Belgium, Brazil, Canada, Czechia, Germany, Israel, Japan, Mexico, Netherlands, Philippines, Spain, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT03068130. Allocation not applicable; no masking; primary purpose treatment. Start 2017-04-18 (actual); primary completion 2020-09-30 (actual). Results posted on 2023-10-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER
- Acronym
- RANGER
- Condition
- Pulmonary Hypertension
- Intervention (Drug)
- Bardoxolone methyl
- Lead sponsor
- Biogen
Record details
- Record id
cardio:ct-nct03068130- Content hash
7b2b69098925fc7aa98486cdd641a591c098cd1fc584a6b5f50f6d19a0a9b88c